Form 4 for OLMA Olema Pharmaceuticals, Inc.
Accepted 2024-05-02 00:00:00 ET · period of report 2024-04-30 · accession 0001415889-24-012020 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-05-02 | 2024-04-30 | OLMA | Harmon Cyrus | Dir | S - Sale | $9.51 | -15.0K | 811.3K | -2% | -$142.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-04-30 | S | D | 15,000 | $9.51 | 811,283 | D | — | — | (F2) The weighted average sale price for the transaction reported was $9.51, and the range of prices was between $9.20 and $9.91. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. |